Clinical Cases in Gastrointestinal Stromal Tumors

A promising new treatment option has emerged for patients with a specific type of gastrointestinal stromal tumor that has become resistant to standard therapy.

In the interview, Alexander Helfand, MD reviewed the latest in gastrointestinal stromal tumor research, and hopes for the future.

After more than 2 years without, the FDA has approved a companion diagnostic to identity candidates for treatment with avapritinib.

In an interview with Targeted Oncology, Antonio Ucar, MD, discussed the evolving role of sunitinib for the second-line treatment of gastrointestinal stromal tumors, and the Peak study.

ctDNA sequencing can efficiently detect KIT/PDGFRA mutations and predict outcomes in patients with tyrosine kinase inhibitor-resistant gastrointestinal stromal tumor treated with avapritinib.

THE-630 will no longer be developed for patients with GIST after patients treated at the 27 mg dose experienced dose-limiting toxicities.